Author

Jacques Turgeon

Montreal - Cited by 8,687 - pharmacy

Biography

Dr. Jacques Turgeon is a Chief Scientific Officer at Tabula Rasa HealthCare Chief Executive Officer, TRHC Scientific Precision Pharmacotherapy Research & Development Institute Professor Emeritus, Faculty of Pharmacy, Université de Montréal Fellow, Canadian Academy of Health Sciences Fellow, Académie nationale de Médecine, France
Title
Cited by
Year
Chronic inflammatory status observed in patients with type 2 diabetes induces modulation of cytochrome P450 expression and activity
L Darakjian, M Deodhar, J Turgeon, V MichaudInternational journal of molecular sciences 22 (9), 4967, 2021202
29
2021
Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol
C Bardolia, NS Amin, J TurgeonFrontiers in Cardiovascular Medicine 8, 789931, 2021202
28
2021
Quantifying anticholinergic burden and sedative load in older adults with polypharmacy: a systematic review of risk scales and models
SB Al Rihani, M Deodhar, LI Darakjian, P Dow, MK Smith, R Bikmetov, ...Drugs & Aging, 1-18, 2021202
24
2021
Assessing the mechanism of fluoxetine-mediated CYP2D6 inhibition
M Deodhar, SBA Rihani, L Darakjian, J Turgeon, V MichaudPharmaceutics 13 (2), 148, 202
21
2021
Longitudinal association of a medication risk score with mortality among ambulatory patients acquired through electronic health record data
AR Ratigan, V Michaud, J Turgeon, R Bikmetov, GG Villarreal, ...Journal of Patient Safety 17 (4), 249, 212
20
2021
Disease-induced modulation of drug transporters at the blood–brain barrier level
SB Al Rihani, LI Darakjian, M Deodhar, P Dow, J Turgeon, V MichaudInternational Journal of Molecular Sciences 22 (7), 3742, 212
20
2021
Association of the MedWise Risk Score with health care outcomes.
V Michaud, MK Smith, R Bikmetov, P Dow, J Johnson, A Stein, S Finnel, ...American Journal of Managed Care 27, 2021202
16
2021
Medication-related problems identified by pharmacists in an enhanced medication therapy management model.
D Bankes, K Pizzolato, S Finnel, MS Awadalla, A Stein, J Johnson, ...American Journal of Managed Care 27, 2021202
13
2021
Contribution of CYP2D6 functional activity to oxycodone efficacy in pain management: Genetic polymorphisms, phenoconversion, and tissue-selective metabolism
M Deodhar, J Turgeon, V MichaudPharmaceutics (9), 1466, 2021202
13
2021
Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and …
T Long, R Cristofoletti, B Cicali, V Michaud, P Dow, J Turgeon, S SchmidtThe Journal of Clinical Pharmacology 62 (1), 76-86, 2022202
9
2022
Classification and assessment of medication risk in the elderly (CARE): use of a medication risk score to inform patients’ readmission likelihood after hospital discharge
S SanFilippo, V Michaud, J Wei, R Bikmetov, J Turgeon, L BrunettiJournal of Clinical Medicine 10 (1), 394, 2021202
7
2021
Determination of CYP450 expression levels in the human small intestine by mass spectrometry-based targeted proteomics
A Grangeon, V Clermont, A Barama, F Gaudette, J Turgeon, V MichaudInternational Journal of Molecular Sciences 22 (23), 12791, 2021202
6
2021
Health outcomes from an innovative enhanced medication therapy management model.
A Stein, S Finnel, D Bankes, H Jin, MS Awadalla, J Johnson, J TurgeonAmerican Journal of Managed Care 27, 2021202
6
2021
Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications
J Turgeon, LE Steffen, G Badea, V MichaudUS Patent 10,890,577, 2021202
6
2021
Use of drug claims data and a medication risk score to assess the impact of CYP2D6 drug interactions among opioid users on healthcare costs
V Michaud, R Bikmetov, MK Smith, P Dow, LI Darakjian, M Deodhar, ...Journal of Personalized Medicine 11 (11), 1174, 2021202
5
2021
Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
MK Smith, R Bikmetov, SB Al Rihani, M Deodhar, M Hafermann, P Dow, ...Clinical and Translational Science 14 (), 1799-1809, 2021202
5
2021
Population-based medication risk stratification and personalized medication risk score
J Turgeon, V Michaud, B CicaliUS Patent 11,361,856, 2022202
4
2022
Pharmacist‐driven interventions to de‐escalate urinary antimuscarinics in the Programs of All‐Inclusive Care for the Elderly
M Ha, A Furman, SB Al Rihani, V Michaud, J Turgeon, DL BankesJournal of the American Geriatrics Society 70 (11), 3230-3238, 2022202
4
2022
Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report
NM Del Toro-Pagán, A Matos, C Bardolia, V Michaud, J Turgeon, ...BMC psychiatry 22 (1), 46, 2022202
3
2022
Pharmacist-led medication evaluation considering pharmacogenomics and drug-induced phenoconversion in the treatment of multiple comorbidities: a case report
NM Del Toro-Pagán, A Matos, D Thacker, J Turgeon, NS Amin, V MichaudMedicina 57 (9), 955, 2021202
3
2021

Referred From: https://scholar.google.com/citations?user=LQmfD5MAAAAJ&hl=en

Cited by
Citations 8687
h-index 48
i10-index 144
Recommended Journals
Open Access Journals